# Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

> **NCT04597242** · — · NO_LONGER_AVAILABLE · sponsor: **ContraFect**

## Conditions studied

- MRSA Bloodstream Infection
- MRSA Bacteremia
- MRSA Right-sided Endocarditis
- Covid19

## Interventions

- **DRUG:** Exebacase

## Key facts

- **NCT ID:** NCT04597242
- **Lead sponsor:** ContraFect
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04597242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04597242, "Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04597242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*